Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.repc.2021.06.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches.
Int J Med Sci
January 2025
Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, People's Republic of China.
Elevated lipoprotein(a) [Lp(a)] levels are increasingly recognized as a significant risk factor for cardiovascular diseases and may also contribute to atrial fibrillation (AF). This review investigated the indirect mechanisms through which Lp(a) may influence AF, including proatherogenic, prothrombotic, and proinflammatory pathways. Traditional lipid-lowering therapies, such as lifestyle modifications and statins, have limited effects on Lp(a) levels.
View Article and Find Full Text PDFReduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.
Int J Mol Sci
December 2024
Department of Clinical Chemistry, Medical University of Gdańsk, 80-211 Gdańsk, Poland.
Oxidative modifications of lipoproteins play a crucial role in the initiation of atherosclerotic cardiovascular diseases (ASCVDs). Nowadays, the one effective strategy for the treatment of patients with hyperlipoproteinemia(a) is lipoprotein apheresis (LA), which has a pleiotropic effect on reducing the risk of ASCVDs. The significance of oxidative susceptibility of the LDL fraction in ASCVDs has been extensively studied.
View Article and Find Full Text PDFThe influence of lipoprotein(a) on aortic valve calcification in patients undergoing transcatheter aortic valve replacement.
Clin Res Cardiol
December 2024
Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Georgstraße 11, 32545, Bad Oeynhausen, Germany.
Background: Elevated levels of lipoprotein(a) (Lp[a]) have been recognized as substantial risk factors for cardiovascular disease and aortic stenosis (AS). However, the specific role of Lp(a) in promoting aortic valve calcification (AVC) and influencing mortality in elderly, multimorbid patients undergoing transcatheter aortic valve replacement (TAVR) remains unclear and warrants further investigation.
Methods: A retrospective analysis was conducted on all consecutive patients who underwent TAVR between August 2019 and June 2020 at our clinic.
Lipoprotein(a) in clinical practice: The role in long-term in-stent restenosis.
J Clin Lipidol
October 2024
Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias, Fondazione Toscana, Gabriele Monasterio, Pisa, Italy.
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review.
Cureus
September 2024
Psychiatry, Inside Out CURE Psychiatry LLC, Princeton, USA.
Article Synopsis
- Lipoprotein(a) [Lp(a)] is recognized as a key independent risk factor for atherosclerotic cardiovascular disease (ASCVD), prompting research into various lipid-lowering drugs that might reduce its levels.
- A systematic review of 29 studies showed that traditional lipid-lowering agents like statins and fibrates generally do not significantly affect Lp(a) concentrations, whereas Lp(a) apheresis and PCSK-9 inhibitors were effective.
- Emerging RNA-targeting therapies, such as anti-sense oligonucleotides, demonstrated promise in lowering Lp(a) levels, but it's still unclear if these reductions will lead to fewer cardiovascular events in patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!